Programmes
Discover our current research programme, which highlights our commitment to groundbreaking studies and treatments, based on our expertise in iron metabolism and cell cycle biology.
Patients who receive frequent blood transfusions may accumulate excess iron in their bodies, which can lead to serious health complications if not properly managed.
Exploring a new approach to iron chelation
Petadeferitrin has a distinct chemical structure compared to existing iron chelators. In early research, the compound has been studied for its ability to bind to iron and form complexes that may be excreted by the body. Ongoing preclinical and clinical development aims to further understand its properties, including distribution in tissues and potential role in future iron chelation therapy.
Shaping the future of iron overload
Iron overload and its management remain important areas of global health research. At Pharmacosmos, we are dedicated to pioneering research into new approaches and to building strong partnerships worldwide to shape the future of care in this field.
We are seeking partners in markets where we do not currently have affiliates, including Japan, Southeast Asia, Latin America, Southern Europe, and the Middle East.
Petadeferitrin is investigational and have not been approved for commercial use anywhere in the world. Safety and efficacy have not been established.
Pharmacosmos is...
A global pioneer in carbohydrate chemistry and a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anaemia.
